(89 days)
The angiographic X-ray systems are indicated for use in generating fluoroscopic and rotational images of human anatomy for cardiovascular, vascular and non-vascular, diagnostic and interventional procedures. Additionally, with the OR table, the angiographic X-ray systems are indicated for use in generating fluoroscopic and rotational images of human anatomy for image-guided surgical procedures. The OR table is suitable for interventional and surgical procedures.
The proposed device, Discovery IGS 730 is an X-ray angiographic system with a 30cm detector size. The proposed device introduces a new fixed C arm positioner that will be the basis of the Discovery IGS X-ray angiographic systems platform. The proposed device will be offered with 2 product configurations, Interventional and OR configuration. The indications for use are expanded to include image-guided surgical procedures and open surgery procedures for the OR configuration of the product. The X-ray tube, the collimator, the X-ray power unit, the flat panel, the X-ray control and image processing chain are the same as the GE Innova systems.
Here's an analysis of the GE Discovery IGS 730 510(k) submission, focusing on acceptance criteria and study details:
1. Table of Acceptance Criteria and Reported Device Performance
This 510(k) summary does not include explicit acceptance criteria or a direct comparison to reported device performance metrics for the Discovery IGS 730. Instead, it relies on the principle of substantial equivalence to predicate devices. The "performance" claimed is that the Discovery IGS 730 is "as safe and effective as its predicates devices, and its performances to be substantially equivalent to the predicate devices."
The submission focuses on non-clinical verification and validation tests to ensure the system functions as intended and meets safety and performance standards equivalent to existing approved devices. The specific metrics for "acceptance criteria" are implied to be conformance with:
- Functional requirements for angiographic and fluoroscopic X-ray systems.
- Safety standards detailed in Section 9 of the premarket submission (not provided here).
- Performance capabilities comparable to the predicate devices (K111209: INTEGRATED INNOVA - SSI SYSTEM OPTION GE Medical Systems and K090745: Siemens Artis Zee).
Since no specific numerical performance criteria are listed, a table comparing them directly isn't possible from the provided text.
2. Sample Size Used for the Test Set and Data Provenance
- Test Set Sample Size: Not applicable. The submission states, "The subject of this premarket submission, Discovery IGS 730, did not require clinical studies to support substantial equivalence in the intended clinical environment." Therefore, there was no clinical test set for performance evaluation in the context of human data.
- Data Provenance: Not applicable for a clinical test set. The verification and validation tests performed were non-clinical.
3. Number of Experts Used to Establish Ground Truth for the Test Set and Their Qualifications
- Not applicable. As no clinical studies were performed, there was no "ground truth" derived from expert review of clinical data. The "ground truth" for non-clinical testing would be the device's design specifications and regulatory requirements, verified through engineering tests.
4. Adjudication Method for the Test Set
- Not applicable. No clinical test set.
5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study
- No. The submission explicitly states, "The subject of this premarket submission, Discovery IGS 730, did not require clinical studies to support substantial equivalence in the intended clinical environment." Therefore, no MRMC study was conducted.
6. Standalone (Algorithm Only Without Human-in-the-Loop Performance) Study
- Partially applicable, but not for "algorithm only" in the modern sense. While this isn't an AI/algorithm-focused device, the non-clinical verification and validation tests essentially assess the device's standalone performance against its design specifications and safety requirements. However, this is not an "algorithm-only" study as typically understood for AI devices. It's a system-level performance evaluation.
7. Type of Ground Truth Used
- Not applicable for clinical ground truth. For the non-clinical tests, the "ground truth" was established by design specifications, pre-defined performance criteria, and adherence to voluntary standards (as mentioned in Section 9 of the submission). These would include technical specifications for imaging quality, radiation dose, mechanical stability, and software functionality, validated through various engineering and simulated use tests.
8. Sample Size for the Training Set
- Not applicable. This device is a traditional X-ray angiographic system, not an AI or machine learning device that utilizes a "training set" in the context of data-driven model development.
9. How the Ground Truth for the Training Set Was Established
- Not applicable. As there is no training set for an AI model.
Summary of Device Acceptance:
The GE Discovery IGS 730 was accepted based on substantial equivalence to legally marketed predicate devices (K111209 and K090745). This determination was supported by non-clinical verification and validation tests, which demonstrated that the new device met the same functional, safety, and performance standards as its predecessors. The submission emphasizes that the Discovery IGS 730 uses the "same fundamental scientific technology" as its predicate devices, introducing a new fixed C-arm positioner and expanding indications for use to include image-guided surgical procedures. No new clinical studies were deemed necessary to support this claim of substantial equivalence.
{0}------------------------------------------------
FEB 1 4 2012
GE Healthcare 510{k} Premarket Notification Submission Discovery IGS 730
510(k) Summary
In accordance with 21 CFR 807.92 the following summary of information is provided:
| Date Summary was | November 10th, 2011 |
|---|---|
| Prepared:Submitter: | GE HealthcareGE Medical Systems, SCS283 RUE DE LA MINIERE78530 BUC - FRANCET: +33-(0)1-30-70-47-41 |
| Primary Contact Person: | Michel GenuerGE Healthcare (GE Medical Systems, SCS)Regulatory Affairs Leader,283 RUE DE LA MINIERE78530 BUC - FRANCET: +33-(0)1-30-70-47-41Email: michel.genuer@ge.com |
| Secondary Contact Person: | Carol AlloianRegulatory Affairs Leader,GE Healthcare9900 W innovation driveWauwatosa, WI, USA, 53226-4856T: (847) 244-8327F: (847) 589-8524Email: carol.alloian@ge.com |
| Device/Trade Name: | GE Discovery IGS angiographic, fluoroscopic X- ray systems |
| Common/Usual Name: | angiographic, fluoroscopic X- ray system |
| Regulation Description:Regulation number:Product Code:Class:Predicate Device(s): | Angiographic X- ray system892.1600.90 IZI, OWB, JAAIIK111209: INTEGRATED INNOVA - SSI SYSTEM OPTION GE Medical SystemsK090745: Siemens Artis Zee |
| Device Description: | The proposed device, Discovery IGS 730 is an X-ray angiographic system with a 30cm detector size. The proposed device introduces a |
| new fixed C arm positioner that will be the basis of the Discovery IGSX-ray angiographic systems platform. The proposed device will beoffered with 2 product configurations, Interventional and ORconfiguration. The indications for use are expanded to includeimage-guided surgical procedures and open surgery procedures forthe OR configuration of the product.The X-ray tube, the collimator, the X-ray power unit, the flat panel,the X-ray control and image processing chain are the same as theGE Innova systems. | |
| Intended Use:Indications for Use: | The angiographic X-ray systems are indicated for use in generatingfluoroscopic and rotational images of human anatomy forcardiovascular, vascular and non-vascular, diagnostic andinterventional procedures.Additionally, with the OR table, the angiographic X-ray systems areindicated for use in generating fluoroscopic and rotational images ofhuman anatomy for image-guided surgical procedures. The ORtable is suitable for interventional and surgical procedures. |
| Technology: | The proposed Discovery IGS 730 system employs the samefundamental scientific technology as its predicate devices. |
| Determination of SubstantialEquivalence: | Summary of Non-Clinical Tests:Non-clinical verification and validation tests were performed toverify and validate the system functionally for the intended use.The following quality assurance measures were applied to thedevelopment of the system:Risk Analysis Requirements Reviews Design Reviews Testing on unit level (Module verification) Integration testing (System verification) Performance testing (Verification) Safety testing (Verification) Simulated use testing (Validation) |
| The Discovery IGS 730 system is designed in compliance withvoluntary standards as detailed in Section 9 of this premarketsubmission. Verification and Validation (V&V) was performed andpassed. | |
| Summary of Clinical Tests:The subject of this premarket submission, Discovery IGS 730, did notrequire clinical studies to support substantial equivalence in theintended clinical environment. | |
| Conclusion: | GE Healthcare considers the Discovery IGS 730 to be as safe andeffective as its predicates devices, and its performances to besubstantially equivalent to the predicate devices. |
Confidential and Privileged. This document contains confidential and privileged trade secrets and other information of General Electric Co. and os such may not be disclosed to others not employed by General Electric Co. All rights reserved
Image /page/0/Picture/7 description: The image shows the General Electric (GE) logo. The logo consists of the letters "GE" intertwined and enclosed within a circular border. The border has a decorative, wave-like pattern around the letters.
{1}------------------------------------------------
Image /page/1/Picture/0 description: The image shows the General Electric (GE) logo. The logo consists of the letters 'GE' intertwined within a circular border. The design is simple and iconic, representing the company's brand identity.
GE Healthcare 510(k) Premarket Notification Submission Discovery IGS 730
Confidential and Privileged. This document continential ond privileged trode secrets and other
information of General Electric Co. and os such may not be disclosed to others Co. All rights reserved
{2}------------------------------------------------
Image /page/2/Picture/0 description: The image shows the General Electric (GE) logo. The logo consists of the letters 'G' and 'E' intertwined in a stylized, cursive font. The intertwined letters are enclosed within a circular border, which has decorative swirls or flourishes at the top and bottom.
1
GE Healthcare 510(k) Premarket Notification Submission
T
Discovery IGS 730
Confidential and Privileged. This document confidential and privileged trade secrets and other information of General Electric Co. and as such may not be disclosed to others not employed by General Electric Co. All rights reserved
{3}------------------------------------------------
Image /page/3/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features the department's name in a circular arrangement around a stylized emblem. The emblem is a blue graphic of what appears to be an abstract caduceus, a symbol often associated with healthcare organizations.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Room -WO66-G609 Silver Spring, MD 20993-0002
Mr. Michael Genuer Regulatory Affairs Leader GE Healthcare GE Medical System SCS 283 Rue de la Miniere 78530 BUC FRANCE
JUL 3 0 2012
Re: K113403 Trade/Device Name: Discover IGS 730 Regulation Number: 21 CFR 892.1650 Regulation Name: Image-intensified fluoroscopic x-ray system Regulatory Class: II Product Code: OWB, JAA and IZI Dated: November 10, 2011 Received: November 17, 2011
Dear Mr. Genuer:
This letter corrects our substantially equivalent letter of February 14, 2012.
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of
{4}------------------------------------------------
medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely Yours,
Janine M. Morris
Janine M. Morri Acting Director Division of Radiological Devices Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health
Enclosure
{5}------------------------------------------------
Image /page/5/Picture/0 description: The image shows a black and white logo. The logo is circular and contains the letters 'GE' in a stylized, intertwined design. The letters are surrounded by a circular border, giving the logo a classic and recognizable appearance.
GE Healthcare 510(k) Premarket Notification Submission Discovery IGS 730
510(k) Number (if known): To Be Assigned
Device Name: Discovery IGS 730
Indications for Use:
The angiographic X-ray systems are indicated for use in generating fluoroscopic and rotational images of human anatomy for cardiovascular, vascular and non-vascular, diagnostic and interventional procedures.
Additionally, with the OR table, the angiographic X-ray systems are indicated for use in generating fluoroscopic and rotational images of human anatomy for image-guided surgical procedures. The OR table is suitable for interventional and surgical procedures.
Prescription Use_x (Part 21 CFR 801 Subpart D) AND/OR
Over-The-Counter Use_ (Part 21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)
Mary, Stootel
✓ (Division Sign-Off)
Division of Neurological Devices
Office of In Vitro Diagnostic Device Evaluation and Safety
510K KU3403
§ 892.1650 Image-intensified fluoroscopic x-ray system.
(a)
Identification. An image-intensified fluoroscopic x-ray system is a device intended to visualize anatomical structures by converting a pattern of x-radiation into a visible image through electronic amplification. This generic type of device may include signal analysis and display equipment, patient and equipment supports, component parts, and accessories.(b)
Classification. Class II (special controls). An anthrogram tray or radiology dental tray intended for use with an image-intensified fluoroscopic x-ray system only is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 892.9. In addition, when intended as an accessory to the device described in paragraph (a) of this section, the fluoroscopic compression device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 892.9.